Melatonin uses in oncology: Breast cancer prevention and reduction of the side effects of chemotherapy and radiation

Expert Opinion on Investigational Drugs

Volumn 21, Issue 6, 2012, Pages 819-831

  Sanchez Barcelo, Emilio J ^a   Mediavilla, Maria D ^a   Alonso Gonzalez, Carolina ^a   Reiter, Russel J ^b  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Breast cancer; Chemo prevention; Chemotherapy; Melatonin; Radiotherapy; SEEM; SERM

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; ANTHRACYCLINE; ANTIESTROGEN; AROMATASE INHIBITOR; ARZOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; COLECALCIFEROL DERIVATIVE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FORMESTANE; GONADOTROPIN; INDOLEAMINE; LASOFOXIFENE; LETROZOLE; MELATONIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; RALOXIFENE; RETINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C RECEPTOR; STATIN; STEROID HORMONE; TAMOXIFEN; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ASTHENIA; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CELL CYCLE; CELL DIFFERENTIATION; CHEMORADIOTHERAPY; CIRCADIAN RHYTHM; DEPRESSION; DISEASE ASSOCIATION; DRUG BINDING; ENZYME ACTIVITY; EPIGENETICS; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; FEMALE; GONADOTROPIN RELEASE; HOT FLUSH; HUMAN; HYPOTENSION; LEUKOPENIA; METASTASIS INHIBITION; MOOD DISORDER; NAUSEA AND VOMITING; NONHUMAN; OBESITY; ONCOLOGY; OSTEOPOROSIS; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; SUSCEPTIBLE POPULATION; THROMBOCYTOPENIA; VAGINAL DRYNESS; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MELATONIN; OXIDATIVE STRESS; RADIATION INJURIES; RISK FACTORS;

EID: 84861068106     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.681045     Document Type: Review

References (101)

1. Hardeland R, Cardinali DP, Srinivasan V, et al. Melatonin-a pleiotropic, orchestrating regulator molecule. Prog Neurobiol 2011;93:350-84
2. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, et al. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 2010;17:4462-81
3. Sanchez-Barcelo EJ, Mediavilla MD, Tan DX, et al. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010;17:2070-95 .
4. Waldhauser F, Boepple PA, Schemper M, et al. Serum melatonin in central precocious puberty is lower than in age-matched prepubertal children. J Clin Endocrinol Metab 1991;73:793-6 (Pubitemid 21921940)
5. Walker AB, English J, Arendt J, et al. Hypogonadotrophic hypogonadism and primary amenorrhoea associated with increased melatonin secretion from a cystic pineal lesion. Clin Endocrinol (Oxf) 1996;45:353-6 (Pubitemid 26306704)
6. Voordouw BC, Euser R, Verdonk RE, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 1992;74:108-17
7. Chowdhury VS, Yamamoto K, Ubuka T, et al. Melatonin stimulates the release of gonadotropin-inhibitory hormone by the avian hypothalamus. Endocrinology 2010;151:271-80
8. Ubuka T, Morgan K, Pawson AJ, et al. Identification of human GnIH homologs, RFRP-1 and RFRP-3, and the cognate receptor, GPR147 in the human hypothalamic pituitary axis. PLoS One 2009;4:e8400
9. Sanchez-Barcelo EJ, Cos S, Mediavilla D, et al. Melatonin-estrogen interactions in breast cancer. J Pineal Res 2005;38:217-22 (Pubitemid 41475432)
10. Ram PT, Dai J, Yuan L, et al. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 2002;179:141-50 (Pubitemid 34215105)
11. Dillon DC, Easley SE, Asch BB, et al. Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol 2002;118:451-8 (Pubitemid 37046344)
12. Hill SM, Cheng C, Yuan L, et al. Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin. Breast Cancer Res Treat 2011;127:91-8
13. Li L, Sacks DB. Functional interactions between calmodulin and estrogen receptor-alpha. Cell Signal 2007;19:439-43 (Pubitemid 46107816)
14. Soto-Vega E, Meza I, Ramirez-Rodriguez G, et al. Melatonin stimulates calmodulin phosphorylation by protein kinase C. J Pineal Res 2004;37:98-106 (Pubitemid 39120213)
15. Garcia Pedrero JM, Del Rio B, Martinez-Campa C, et al. Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol 2002;16:947-60 . (Pubitemid 34478533)
16. Dong C, Yuan L, Dai J, et al. Melatonin inhibits mitogenic cross-talk between retinoic acid-related orphan receptor alpha (RORalpha) and ERalpha in MCF-7 human breast cancer cells. Steroids 2010;75:944-51
17. Cos S, Gonzalez A, Martinez-Campa C, et al. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets 2008;8:691-702
18. Gonzalez A, Alvarez-Garcia V, Martinez-Campa C, et al. In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin. Curr Cancer Drug Targets 2010;10:279-86
19. Martinez-Campa C, Gonzalez A, Mediavilla MD, et al. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer 2009;101:1613-19
20. Gonzalez A, Cos S, Martinez-Campa C, et al. Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res 2008;45:86-92 (Pubitemid 351986266)
21. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996;32A:30-8
22. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011;51:1-16
23. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004;36:11-19
24. Pozo D, Reiter RJ, Calvo JR, et al. Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. J Cell Biochem 1997;65:430-42 (Pubitemid 27190697)
25. Karbownik M, Lewinski A, Reiter RJ. Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int J Biochem Cell Biol 2001;33:735-53 (Pubitemid 32524173)
26. Perks CM, Holly JM. Hormonal mechanisms underlying the relationship between obesity and breast cancer. Endocrinol Metab Clin North Am 2011;40:485-507
27. Carpenter CL, Ross RK, Paganini-Hill A, et al. Effect of family history, obesity and exercise on breast cancer risk among postmenopausal women. Int J Cancer 2003;106:96-102 (Pubitemid 36750394)
28. Yue W, Santner SJ, Masamura S, et al. Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Breast Cancer Res Treat 1998;49(Suppl 1):S1-7.discussion S33-7 (Pubitemid 128689724)
29. Kabat GC, Kim M, Caan BJ, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 2009;125:2704-10
30. Smith-Kirwin SM, O'Connor DM, De Johnston J, et al. Leptin expression in human mammary epithelial cells and breast milk. J Clin Endocrinol Metab 1998;83:1810-13 (Pubitemid 28501064)
31. Shimizu H, Shimomura Y, Nakanishi Y, et al. Estrogen increases in vivo leptin production in rats and human subjects. J Endocrinol 1997;154:285-92 (Pubitemid 27330641)
32. Gonzalez-Perez RR, Xu Y, Guo S, et al. Leptin upregulates VEGF in breast cancer via canonic and non-canonical signaling pathways and NFkappaB/HIF-1alpha activation. Cell Signal 2010;22:1350-62
33. Meng L, Zhou J, Sasano H, et al. Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction. Cancer Res 2001;61:2250-5 (Pubitemid 32692055)
34. Bulun SE, Lin Z, Imir G, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359-83 (Pubitemid 41196955)
35. Cavalieri E, Frenkel K, Liehr JG, et al. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000(27):75-93
36. Chlebowski RT, Hendrix SL, Langer RD, et al. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53 (Pubitemid 37430077)
37. Clarke CA, Glaser SL, Uratsu CS, et al. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006;24:e49-50
38. Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev 2010;19:2496-502
39. Reiter RJ, Tan DX, Korkmaz A, et al. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit Rev Oncog 2007;13:303-28 (Pubitemid 351655045)
40. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 2001;93:1563-8 (Pubitemid 32998486)
41. Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 2010;19:729-37
42. Oh EY, Ansell C, Nawaz H, et al. Global breast cancer seasonality. Breast Cancer Res Treat 2010;123:233-43
43. Blask DE, Hill SM, Dauchi RT, et al. Circadian regulation of molecular, dietary, and metabolic signaling mechanisms on human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. J Pineal Res 2011;51:259-69
44. Cos S, Mediavilla D, Martinez-Campa C, et al. Exposure to light-at-night increases the growth of DMBA-induced mammary adenocarcinomas in rats. Cancer Lett 2006;235:266-71
45. Blask DE, Brainard GC, Dauchy RT, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005;65:11174-84 (Pubitemid 41713389)
46. Hardeland R, Madrid JA, Tan DX. Melatonin, the circadian multioscilator system and health: the need for detailed analyses of peripheral melatonin signals. J Pineal Res 2012;52:139-66 .
47. Cuzick J, De Censi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet 2011;12:496-503
48. Lorizio W, Wu AH, Beattie MS, et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 2011; Epub ahead of print
49. Martino S, Cauley JA, Barrett-Connor E, et al. CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61 (Pubitemid 39654569)
50. Barrett-Connor E, Cauley JA, Kulkarni PM, et al. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res 2004;19:1270-5 (Pubitemid 41094367)
51. Vogel VG, Costantino JP, Wickerham DL, et al. National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696-706
52. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96
53. Cummings SR, McClung M, Reginster JY, et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 2011;26:397-404
54. Cos S, Sanchez-Barcelo EJ. Melatonin and mammary pathological growth. Front Neuroendocrinol 2000;21:133-70 (Pubitemid 30228502)
55. Lenoir V, de Jonage-Canonico MB, Perrin MH, et al. Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz [a]anthracene in the female Sprague-Dawley rat. Breast Cancer Res 2005;7:R470-6
56. Karbownik M, Reiter RJ, Burkhardt S, et al. Melatonin attenuates estradiol-induced oxidative damage to DNA: relevance for cancer prevention. Exp Biol Med (Maywood) 2001;226:707-12 (Pubitemid 32619611)
57. Nduhirabandi F, du Toit EF, Lochner A. Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? Acta Physiol (Oxf) 2012; [Epub ahead of print]
58. Tan DX, Manchester LC, Fuentes-Broto L, et al. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev 2011;12:167-88
59. Kozirog M, Poliwczak AR, Duchnowicz P, et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res 2011;50:261-6
60. Knight JA, Thompson S, Raboud JM, et al. Light and exercise and melatonin production in women. Am J Epidemiol 2005;162:1114-22 (Pubitemid 41746624)
61. Cohen M, Small RA, Brzezinski A. Hypotheses: melatonin/steroid combination contraceptives will prevent breast cancer. Breast Cancer Res Treat 1995;33:257-64
62. Witt-Enderby PA, Radio NM, Doctor JS, et al. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res 2006;41:297-305 (Pubitemid 44498215)
63. Celinski K, Konturek SJ, Konturek PC, et al. Melatonin or L-tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole. J Pineal Res 2011;50:389-94
64. West KE, Jablonski MR, Warfield B, et al. Blue light from light-emitting diodes elicits a dose-dependent suppression of melatonin in humans. J Appl Physiol 2011;110:619-26
65. Provencio I, Rodriguez IR, Jiang G, et al. A novel human opsin in the inner retina. J Neurosci 2000;20:600-5 (Pubitemid 30225562)
66. Sasseville A, Paquet N, Sevigny J, et al. Blue blocker glasses impede the capacity of bright light to suppress melatonin production. J Pineal Res 2006;41:73-8 (Pubitemid 43980698)
67. Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 1995;71:854-6
68. Martinez-Campa C, Gonzalez A, Mediavilla MD, et al. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer 2009;101:1613-19
69. Anisimov VN, Egormin PA, Piskunova TS, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010;9:188-97
70. Proietti S, Cucina A, D'Anselmi F, et al. Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFbeta-1-dependent growth inhibition of breast cancer cells. J Pineal Res 2011;50:150-8
71. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:1707-16
72. Sautter-Bihl ML, Souchon R, Gerber B. Adjuvant therapy for women over age 65 with breast cancer. Dtsch Arztebl Int 2011;108:365-71
73. Bourgier C, Calvo FA, Marsiglia H, et al. Overview of preoperative radiochemotherapy in breast cancer: past or future? Clin Transl Oncol 2011;13:446-50
74. Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008;123:1227-39
75. Lawenda BD, Kelly KM, Ladas EJ, et al. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 2008;100:773-83 (Pubitemid 351809666)
76. Shirazi A, Ghobadi G, Ghazi-Khansari M. A radiobiological review on melatonin: a novel radioprotector. J Radiat Res (Tokyo) 2007;48:263-72 (Pubitemid 47105598)
77. Shirazi A, Mihandoost E, Mohseni M, et al. Radio-protective effects of melatonin against irradiation-induced oxidative damage in rat peripheral blood. Phys Med 2011; [Epub ahead of print]
78. Seely D, Wu P, Fritz H, et al. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther 2011; [Epub ahead of print] .
79. Ambrosone CB, Tian C, Ahn J, et al. Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res 2006;8:R40
80. Vasin MV, Ushakov IB, Kovtun VI, et al. Comparative effectiveness of antioxidant melatonin and radioprotectors indralin and phenylephrine in local radiation injuries]. Radiats Biol Radioecol 2004;44:68-71
81. Schaffazick SR, Pohlmann AR, Guterres SS. Nanocapsules, nanoemulsion and nanodispersion containing melatonin: preparation, characterization and stability evaluation. Pharmazie 2007;62:354-60 (Pubitemid 46847938)
82. Dziegiel P, Suder E, Surowiak P, et al. Role of exogenous melatonin in reducing the nephrotoxic effect of daunorubicin and doxorubicin in the rat. J Pineal Res 2002;33:95-100 (Pubitemid 34913486)
83. Oz E, Erbas D, Surucu HS, et al. Prevention of doxorubicin-induced cardiotoxicity by melatonin. Mol Cell Biochem 2006;282:31-7 (Pubitemid 43019460)
84. Catala A, Zvara A, Puskas LG, et al. Melatonin-induced gene expression changes and its preventive effects on adriamycin-induced lipid peroxidation in rat liver. J Pineal Res 2007;42:43-9 (Pubitemid 44924324)
85. Johnston SR. The role of chemotherapy and targeted agents in patients with metastatic breast cancer. Eur J Cancer 2011;47.S38-47
86. Lissoni P, Tancini G, Paolorossi F, et al. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. J Pineal Res 1999;26:169-73 (Pubitemid 29183120)
87. Watanabe M, Kobayashi Y, Takahashi N, et al. Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line. J Obstet Gynaecol Res 2008;34:567-73
88. Nahleh Z, Pruemer J, Lafollette J, et al. Melatonin, a promising role in taxane-related neuropathy. Clin Med Insights Oncol 2010;4:35-41
89. Hassan MI, Ahmed MI, Kassim SK, et al. Cis-platinum-induced immunosuppression: relationship to melatonin in human peripheral blood mononuclear cells. Clin Biochem 1999;32:621-6 (Pubitemid 30039090)
90. Hara M, Yoshida M, Nishijima H, et al. Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res 2001;30:129-38 (Pubitemid 32245283)
91. Luo J, Tsuji T, Yasuda H, et al. The molecular mechanisms of the attenuation of cisplatin-induced acute renal failure by N-acetylcysteine in rats. Nephrol Dial Transplant 2008;23:2198-205 (Pubitemid 351957613)
92. Ruiz-Rabelo J, Vazquez R, Arjona A, et al. Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer. Pancreas 2011;40:410-14
93. Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris) 2007;55:201-4 (Pubitemid 46829640)
94. Lu WJ, Desta Z, Flockhart DA. Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat 2012;131:473-81
95. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693
96. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011;378:621-31
97. Savard J, Simard S, Blanchet J, et al. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep 2001;24:583-90 (Pubitemid 32660384)
98. Berger AM, Wielgus K, Hertzog M, et al. Patterns of circadian activity rhythms and their relationships with fatigue and anxiety/depression in women treated with breast cancer adjuvant chemotherapy. Support Care Cancer 2010;18:105-14
99. Cardinali DP, Srinivasan V, Brzezinski A, et al. Melatonin and its analogs in insomnia and depression. J Pineal Res 2011; [Epub ahead of print]
100. Hermelink K, Untch M, Lux MP, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007;109:1905-13 (Pubitemid 46668557)
101. Hansen MV, Madsen MT, Hageman I, et al. The effect of MELatOnin on depression, anxiety, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: protocol for a randomised, placebo-controlled, double-blinded trial. BMJ Open 2012;2:e000647